Gastroenterology

On-Demand Webcast 1
Optimal Management of HBV: A Partnership
Between Primary Care and Specialty Physicians

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

Optimal Management of HBV:
A Partnership Between Primary Care
and Specialty Physicians
On-Demand Webcast 1

View Webcast - requires Flash & high-speed Internet (Tech. Requirements)
View/Download Slides
View/Download Syllabus
Certificate Program Course List

Dear Colleague,

If you missed the live HBV audioconference held on June 29, 2006, here is your second chance to participate in this outstanding educational activity. Optimal Management of HBV: A Partnership Between Primary Care and Specialty Physicians is now available as an on-demand webcast, the first of three offered as part of Advanced Certificate Program II: Management of Chronic Hepatitis B.

This 1-hour webcast, led by Robert G. Gish, MD, and W. Ray Kim, MD, focuses on why it is important for clinicians to collaborate in order to optimize the management of patients with HBV infection. Covered topics include screening and testing patients, identifying candidates for therapy, evaluating treatment options based on current guidelines and available agents, as well as monitoring and follow-up care. Presentation slides and syllabus are also available for download. The webcast concludes with the Q&A session from the live audioconference.

Take advantage of this important and informative educational activity, at any time at your convenience! View the webcast now!

Sincerely,

CO-CHAIR
Robert G. Gish, MD Medical Director Liver Transplant Program Chief, Division of Hepatology and Complex GI California Pacific Medical Center San Francisco, California
Adrian M. Di Bisceglie, MD, FACP, and Robert G. Gish, MD, co-chairs of Advanced Certificate Program II: Management of Chronic Hepatitis B, alternate to help develop content for the audioconferences. This audioconference was developed by Dr. Robert G. Gish and Dr. W. Ray Kim.
FACULTY W. Ray Kim, MD Associate Professor of Medicine Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota

top

TARGET AUDIENCE

This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.

ACTIVITY GOAL

The goal of this CME/CE activity is to examine current and emerging strategies for diagnosing and treating patients infected with HBV.

LEARNING OBJECTIVES

For patients with risk factors for hepatitis B, employ serologic screening tests to successfully identify those who are infected
In HBV-infected patients, evaluate those who may be candidates for treatment based on current guidelines
Integrate customized treatment regimens for patients with chronic HBV infection that will suppress serum HBV DNA levels

top

CME INFORMATION—PHYSICIANS

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

CME INFORMATION—PHYSICIAN ASSISTANTS

Projects In Knowledge will issue a certificate of participation for each course the participant completes. Please check with your organization and/or society for reciprocity.

CE INFORMATION—NURSES

This activity has been approved by the American Association of Critical-Care Nurses (AACN) for a maximum of 1.5 contact hours. Provider #00012705.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Robert G. Gish, MD, has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, Idun Pharmaceuticals, Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and XTL Biopharmaceuticals; is a consultant for Amgen Inc, Anadys Pharmaceuticals, Inc, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, Innogenetics, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Nucleonics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals International, XTL Biopharmaceuticals, and ZymoGenetics, Inc; and is on the speakers bureau of Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Eximias Pharmaceutical Corporation, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, InterMune Inc, Ortho Biotech Products LP, Schering-Plough Corporation, and Valeant Pharmaceuticals International.

W. Ray Kim, MD, has received grant/research support from Idenix Pharmaceuticals.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

This CME/CE activity will include a discussion of the unlabeled/unapproved uses of emtricitibine, hepatitis A vaccine, hepatitis B vaccine, a discussion of combination hepatitis A and B vaccine, and tenofovir.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME/CE activity is supported by an educational grant from Bristol-Myers Squibb Company.

top

1763

Optimal Management of HBV: A Partnership Between Primary Care and Specialty Physicians On-Demand Webcast 1

Optimal Management of HBV:
A Partnership Between Primary Care
and Specialty Physicians
On-Demand Webcast 1